Recon: FDA approves Novo’s Wegovy to lower cardiovascular risks; Acadia’s schizophrenia drug misses primary goal in Phase 3 trial
ReconMichael Mezher
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States